Ruling out 131I ablation in low-risk differentiated thyroid carcinoma basing on thyroglobulin measurement.

[1]  L. Ceriani,et al.  Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body Scan , 2011, Clinical nuclear medicine.

[2]  P. Rosário,et al.  Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and ¹³¹I activity in patients with thyroid cancer and low risk of recurrence. , 2011, Thyroid : official journal of the American Thyroid Association.

[3]  S. Larson,et al.  The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer , 2010, The Journal of Nuclear Medicine.

[4]  M. Salvatori,et al.  Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[6]  J. Krahn,et al.  Thyroglobulin and anti-thyroglobulin assays in thyroid cancer monitoring. , 2009, Clinical biochemistry.

[7]  D. Lee,et al.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  L. Ceriani,et al.  Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy , 2007, Clinical endocrinology.

[9]  P. Ladenson,et al.  Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. , 2005, The New England journal of medicine.

[10]  Á. Barroso,et al.  Correlation Between Cervical Uptake and Results of Postsurgical Radioiodine Ablation in Patients With Thyroid Carcinoma , 2004, Clinical nuclear medicine.

[11]  L. Giovanella.  Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management , 2008, Clinical chemistry and laboratory medicine.

[12]  B. Wolffenbuttel,et al.  The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. , 2008, European journal of endocrinology.